JP2009539862A - 強化剤を含む固体経口投与剤形 - Google Patents

強化剤を含む固体経口投与剤形 Download PDF

Info

Publication number
JP2009539862A
JP2009539862A JP2009514424A JP2009514424A JP2009539862A JP 2009539862 A JP2009539862 A JP 2009539862A JP 2009514424 A JP2009514424 A JP 2009514424A JP 2009514424 A JP2009514424 A JP 2009514424A JP 2009539862 A JP2009539862 A JP 2009539862A
Authority
JP
Japan
Prior art keywords
acid
dosage form
composition
derivative
enhancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009514424A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009539862A5 (https=
Inventor
レオナード，トーマス，ダブリュ．
オトゥール，エデル
フィーニー，オーラ
Original Assignee
メリオン リサーチ Ｉｉｉ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メリオン リサーチ Ｉｉｉ リミテッド filed Critical メリオン リサーチ Ｉｉｉ リミテッド
Publication of JP2009539862A publication Critical patent/JP2009539862A/ja
Publication of JP2009539862A5 publication Critical patent/JP2009539862A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009514424A 2006-06-09 2007-06-11 強化剤を含む固体経口投与剤形 Pending JP2009539862A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81252306P 2006-06-09 2006-06-09
PCT/US2007/013693 WO2007146234A2 (en) 2006-06-09 2007-06-11 Solid oral dosage form containing an enhancer

Publications (2)

Publication Number Publication Date
JP2009539862A true JP2009539862A (ja) 2009-11-19
JP2009539862A5 JP2009539862A5 (https=) 2010-07-01

Family

ID=38832458

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009514424A Pending JP2009539862A (ja) 2006-06-09 2007-06-11 強化剤を含む固体経口投与剤形

Country Status (5)

Country Link
US (1) US20070292512A1 (https=)
EP (1) EP2040731A4 (https=)
JP (1) JP2009539862A (https=)
CA (1) CA2654566A1 (https=)
WO (1) WO2007146234A2 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
CA2563533C (en) * 2004-04-15 2013-10-01 Shmuel A. Ben-Sasson Compositions capable of facilitating penetration across a biological barrier
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
JP5156392B2 (ja) 2005-02-03 2013-03-06 トポターゲット ユーケー リミテッド Ｈｄａｃ阻害剤を用いる併用療法
ATE542527T1 (de) 2005-05-13 2012-02-15 Topotarget Uk Ltd Pharmazeutische formulierungen von hdac-hemmern
IN2013CH00226A (https=) * 2013-01-17 2015-08-07 Benny Antony
WO2007054719A2 (en) 2005-11-10 2007-05-18 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
EP2012801A4 (en) * 2006-04-24 2009-08-05 Gloucester Pharmaceuticals Inc GEMCITABINE COMBINATION THERAPY
US8957027B2 (en) * 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
AU2007342028B2 (en) * 2006-12-29 2013-06-13 Celgene Corporation Purifiction of romidepsin
CN101687010A (zh) * 2006-12-29 2010-03-31 格洛斯特制药公司 制备Romidepsin
JP2010516767A (ja) * 2007-01-23 2010-05-20 グラスター ファーマシューティカルズ， インコーポレイテッド ロミデプシンおよびｉ．ａ．ボルテゾミブを含む併用療法
US8642809B2 (en) * 2007-09-25 2014-02-04 Topotarget Uk Ltd. Methods of synthesis of certain hydroxamic acid compounds
WO2009108857A2 (en) * 2008-02-27 2009-09-03 Combithera, Inc. Combination therapy for prostate cancer
ES2536208T3 (es) * 2008-03-07 2015-05-21 Onxeo Dk, Branch Of Onxeo S.A., France Métodos de tratamiento que emplean infusión continua prolongada de Belinostat
AR071375A1 (es) 2008-04-22 2010-06-16 Solvay Pharm Gmbh Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto
RU2517135C2 (ru) 2008-05-07 2014-05-27 Меррион Рисерч Iii Лимитед Композиции пептидов и способы их получения
EP2309854A4 (en) * 2008-07-30 2012-06-06 Gloucester Pharmaceuticals Inc ACCELERATED THERAPY:
KR101814186B1 (ko) 2008-09-17 2018-03-14 키아스마 인코포레이티드 약제학적 조성물 및 연관된 투여방법
WO2010065329A2 (en) * 2008-11-25 2010-06-10 The Board Of Regents Of The University Of Texas System Nanoparticles for cancer treatment
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
CA2769633C (en) 2009-07-31 2017-06-06 Thar Pharma, Llc Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
NZ605526A (en) 2010-07-12 2015-04-24 Celgene Corp Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
SI2651398T1 (en) 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
KR20140026354A (ko) 2011-01-07 2014-03-05 메리온 리서치 Ⅲ 리미티드 경구 투여용 철의 제약 조성물
PL2696687T3 (pl) 2011-04-12 2017-06-30 Novo Nordisk A/S Pochodne podwójnie acylowanej GLP-1
CA2849708A1 (en) * 2011-09-23 2013-03-28 Celgene Corporation Romidepsin and 5 - azacitidine for use in treating lymphoma
CA2863291A1 (en) * 2012-01-12 2013-07-18 Celgene Corporation Romidepsin formulations and uses thereof
HRP20181447T1 (hr) 2012-03-22 2018-11-02 Novo Nordisk A/S Pripravci glp-1 peptida i njihova priprava
ES2965469T3 (es) 2012-03-22 2024-04-15 Novo Nordisk As Composiciones que comprenden un agente de suministro y preparación de estas
PT2827845T (pt) 2012-03-22 2019-03-29 Novo Nordisk As Composições compreendendo um agente de entrega e sua preparação
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
KR102272671B1 (ko) 2013-05-02 2021-07-06 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
WO2016126830A1 (en) 2015-02-03 2016-08-11 Chiasma Inc. Method of treating diseases
US20180140722A1 (en) * 2015-04-06 2018-05-24 The University Of North Carolina At Chapel Hill Methods and compositions for treatment of heart failure
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
CN109045001A (zh) * 2018-09-13 2018-12-21 潘治忠 p300活化剂CTPB及其衍生物在提高胶原蛋白Col17A1表达的用途
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537321A (ja) * 1999-02-22 2002-11-05 エラン コーポレイション ピーエルスィー 促進剤を含む固体経口剤形

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US232981A (en) * 1880-10-05 Flobebtt ladey
US105627A (en) * 1870-07-26 Improvement in machinery for cutting wax into sheets
US21378A (en) * 1858-08-31 Improved propeller for boats
US2140A (en) * 1841-06-26 Island
US219131A (en) * 1879-09-02 Improvement in refrigerating apparatus
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
DE3331009A1 (de) * 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
US4590062A (en) * 1984-04-16 1986-05-20 Tech Trade Corp. Dry direct compression compositions for controlled release dosage forms
US4654155A (en) * 1985-03-29 1987-03-31 Reynolds Metals Company Microemulsion lubricant
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US4764375A (en) * 1985-09-11 1988-08-16 Kv Pharmaceutical Company Sachet drug delivery system
US4789547A (en) * 1987-06-17 1988-12-06 Warner-Lambert Company Transdermal matrix system
US5221734A (en) * 1987-10-01 1993-06-22 Ciba-Geigy Corporation Process for preparing a polypeptide growth factor for milk
NO179479C (no) * 1988-03-11 1996-10-16 Teikoku Seiyaku Kk Fremgangsmåte for fremstilling av et intravaginalt farmasöytisk preparat
US5169933A (en) * 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5190748A (en) * 1988-11-22 1993-03-02 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US5541155A (en) * 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
US5229130A (en) * 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
DE4317458A1 (de) * 1992-06-11 1993-12-16 Bayer Ag Verwendung von cyclischen Depsipeptiden mit 18 Ringatomen zur Bekämpfung von Endoparasiten, neue cyclische Depsipeptide mit 18 Ringatomen und Verfahren zu ihrer Herstellung
US5346701A (en) * 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
SE9302135D0 (sv) * 1993-06-18 1993-06-18 Kabi Pharmacia Ab New pharmaceutical composition
ES2068762B1 (es) * 1993-07-21 1995-12-01 Lipotec Sa Un nuevo preparado farmaceutico para mejorar la biodisponibilidad de drogas de dificil absorcion y procedimiento para su obtencion.
US5639469A (en) * 1994-06-15 1997-06-17 Minnesota Mining And Manufacturing Company Transmucosal delivery system
GB9414318D0 (en) * 1994-07-15 1994-09-07 Dowelanco Ltd Preparation of aqueous emulsions
KR100413202B1 (ko) * 1994-11-17 2004-04-13 도레이 가부시끼가이샤 경피흡수제제
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
JPH11505258A (ja) * 1995-05-17 1999-05-18 セダーシナイ メディカル センター 小腸における消化および吸収を改善させる脂肪酸を含む組成物
US6572879B1 (en) * 1995-06-07 2003-06-03 Alza Corporation Formulations for transdermal delivery of pergolide
US5631347A (en) * 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US5932547A (en) * 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
EP0942697A1 (en) * 1996-10-30 1999-09-22 THERATECH, INC. (a Delaware Corporation) Fatty acid esters of lactic acid salts as permeation enhancers
CA2294988C (en) * 1997-07-01 2015-11-24 Isis Pharmaceuticals Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
SE9703691D0 (sv) * 1997-10-10 1997-10-10 Astra Ab Pharmaceutical compositions
US6326360B1 (en) * 1998-03-11 2001-12-04 Grelan Pharmaceuticals Co., Ltd. Bubbling enteric coated preparations
US6270804B1 (en) * 1998-04-03 2001-08-07 Biovail Technologies Ltd. Sachet formulations
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
JP2001081031A (ja) * 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
CN1414971A (zh) * 1999-12-08 2003-04-30 埃克斯西特治疗公司 用作免疫抑制剂的缩肽及其同类物
MXPA02009924A (es) * 2000-04-07 2004-08-19 Univ Texas Composiones unicas de fosfolipidos de ion anfoterico y bisfosfonatos y uso de las composiciones como sistemas de suministro de bisfosfato con toxicidad gi reducida.
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
CN1141974C (zh) * 2000-06-07 2004-03-17 张昊 结肠定位释放的口服生物制剂
AU2002243231A1 (en) * 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
US6379960B1 (en) * 2000-12-06 2002-04-30 Isis Pharmaceuticals, Inc. Antisense modulation of damage-specific DNA binding protein 2, p48 expression
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US7154002B1 (en) * 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
AR047938A1 (es) * 2003-08-25 2006-03-15 Combinatorx Inc Formulaciones, conjugados y combinaciones de farmacos para el tratamiento de neoplasmas
DE10358525A1 (de) * 2003-12-13 2005-07-07 Bayer Healthcare Ag Endoparasitizide Mittel zur topischen Applikation
WO2005062041A1 (en) * 2003-12-24 2005-07-07 Astrazeneca Ab Pharmaceutical dissolution testing using a non-ionic surfactant
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
BRPI0606280A2 (pt) * 2005-03-17 2009-06-09 Elan Pharma Int Ltd composições de bisfosfonato nanoparticulado
IL174387A0 (en) * 2005-03-31 2008-01-20 Dexcel Pharma Technologies Ltd A solid composition for intra-oral delivery of insulin
EP1898930A4 (en) * 2005-06-17 2009-12-09 Dynamis Therapeutics Inc Treatment of inflammatory conditions
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
US20090004281A1 (en) * 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537321A (ja) * 1999-02-22 2002-11-05 エラン コーポレイション ピーエルスィー 促進剤を含む固体経口剤形

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6012032138; ＡＮＮＵ．ＲＥＶ．ＰＨＡＲＭＡＣＯＬ．ＴＯＸＩＣＯＬ． ＶＯＬ．４５, 2005, Ｐ．４９５-５２８，Ｃ-１，Ｃ-２ *
JPN6012032141; ＩＮＶＥＳＴＩＧＡＴＩＯＮＡＬ　ＮＥＷ　ＤＲＵＧＳ ＶＯＬ．１５, 1997, Ｐ．１９５-２０６ *

Also Published As

Publication number Publication date
WO2007146234A3 (en) 2008-02-28
EP2040731A2 (en) 2009-04-01
WO2007146234A8 (en) 2008-09-12
US20070292512A1 (en) 2007-12-20
EP2040731A4 (en) 2010-05-19
CA2654566A1 (en) 2007-12-21
WO2007146234A2 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
JP2009539862A (ja) 強化剤を含む固体経口投与剤形
US20070148228A1 (en) Solid oral dosage form containing an enhancer
US8323690B2 (en) Solid oral dosage form containing an enhancer
EP1154761B1 (en) Solid oral dosage form containing an enhancer
US8883201B2 (en) Solid oral dosage form containing an enhancer
US8119159B2 (en) Solid oral dosage form containing an enhancer
JPWO1994010983A1 (ja) 下部消化管放出性の経口医薬製剤
JP2006507298A (ja) 経口持続放出型錠剤、ならびにその製造法および使用法
WO2001064253A1 (en) P-glycoprotein modifier-containing medicinal compositions to be delivered to the large intestine
AU2013205707A1 (en) Solid oral dosage form containing an enhancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120626

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121120